Drug Trial Radar · NCT02605954
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
Last checked: Nov 20, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
Nov 18, 2015
Primary completion
Jun 14, 2017
Study completion Jan 24, 2018
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.
Conditions
- HIV-1 Infection
Interventions
E/C/F/TAFDrug
150/150/200/10 mg FDC tablets administered orally once daily
ABC/3TCDrug
600/300 mg tablets administered orally once daily
Third Antiretroviral AgentDrug
Third antiretroviral agents could include one of the following: * ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC * DRV+COBI or DRV/COBI FDC * darunavir (DRV; Prezista®) + RTV * lopinavir/ritonavir (LPV/r; Kaletra®) * atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®) * efavirenz (EFV; Sustiva®) * etravirine (ETR; Intelence®) * nevirapine (NVP; Viramune®) * rilpivirine (RPV; Edurant®) * dolutegravir (DTG; Tivicay®) * raltegravir (RAL; Isentress®) * fosamprenavir (FPV; Lexiva®) + RTV * saquinavir (SQV; Invirase®) + RTV * ATV (no booster) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24Time frame: Week 24
Locations
49 sites in 6 countries. Site status is shown where the registry gives one.
Spectrum Medical Group
Phoenix, Arizona
Ruane Clinical Research Group
Los Angeles, California
Capital Medical Associates, P.C.
Washington D.C., District of Columbia
Georgetown University
Washington D.C., District of Columbia
Gary Richmond, MD, PA, Inc.
Fort Lauderdale, Florida
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida
Steinhart Medical Associates dba The Kinder Medical Group
Miami, Florida
Triple O Research Institute PA
West Palm Beach, Florida
The Positive Health Clinic, Allegheny Health Network
Pittsburgh, Pennsylvania
Central Texas Clinical Research
Austin, Texas
AIDS Arms, Inc./Trinity Health & Wellness Center
Dallas, Texas
Tarrant County ID Associates
Fort Worth, Texas
CHU - Groupe Saint-Andre
Bordeaux, France
Hopital Henri Mondor
Créteil, France
Hopital Europeen Marseille
Marseille, France
C.H.U. de Nantes
Nantes, France
C.H.U. de NICE
Nice, France
CHU Hotel Dieu
Paris, France
Hopital Lariboisiere
Paris, France
Hopital Necker les Enfants Malades
Paris, France
Hopital Saint Antoine
Paris, France
Hopital Saint Louis
Paris, France
Centre Hospitalier Gustave Dron
Tourcoing, France
Epimed GmbH
Berlin, Germany
Universitatsklinikum Essen
Essen, Germany
ICH Study Center Hamburg
Hamburg, Germany
Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany
ARNAS Garibaldi - Nesima
Catania, Italy
Unit Infectious Diseases - University of Catania - ARNAS Garibaldi
Catania, Italy
Azienda Ospedaliera Luigi Sacco
Milan, Italy
Azienda Ospedaliero Universitaria Policlinico di Modena
Modena, Italy
Azienda Ospedale San Paolo
Monza, Italy
Azienda Ospedaliera San Gerardo
Monza, Italy
Ospedale Civile S. Spirito AUSL
Pescara, Italy
Unità Operativa Complessa di Malattie Infettive
Pescara, Italy
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.
Roma, Italy
Comprensorio Ospedaliero Amedeo di Savoia
Torino, Italy
Dipartimento di Malattie Infettive e Tropicali
Torino, Italy
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.